Voyager Therapeutics (VYGR) Current Assets (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Current Assets data on file, last reported at $147.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 40.06% year-over-year to $147.0 million; the trailing twelve-month figure through Mar 2026 stood at $147.0 million (down 40.06% YoY), and the FY2025 full-year result was $202.7 million, down 26.78% from the prior year.
• Current Assets declined to $147.0 million in Q1 2026, from $202.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $409.1 million in Q1 2024 to a low of $124.5 million in Q4 2022.
• A 5-year average of $249.6 million and a median of $245.2 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 156.78% in 2023 and sank 41.2% in 2025, its largest moves.
• Tracing VYGR's Current Assets over 5 years: stood at $124.5 million in 2022, then jumped by 156.78% to $319.7 million in 2023, then slipped by 13.41% to $276.8 million in 2024, then decreased by 26.78% to $202.7 million in 2025, then fell by 27.48% to $147.0 million in 2026.
• Business Quant data shows VYGR's Current Assets at $147.0 million in Q1 2026, $202.7 million in Q4 2025, and $219.6 million in Q3 2025.